Difficulty: Medium
Average Score: 63%
Practice
Neostigmine is preferred over physostigmine for treating myasthenia gravis because
Correct answer
C
Rationale
In the treatment of myasthenia gravis, neostigmine is preferred over physostigmine because neostigmine has additional direct agonistic action on nicotinic receptors. This direct agonistic action enhances muscle strength by increasing acetylcholine levels at the neuromuscular junction, which is crucial in managing the symptoms of myasthenia gravis.
Option A, that neostigmine is better absorbed orally, is incorrect as both neostigmine and physostigmine are primarily administered parenterally due to poor oral bioavailability.
Option B, stating that neostigmine has a longer duration of action, is also incorrect. Both drugs have a relatively short duration of action, requiring frequent dosing to maintain therapeutic effects.
Option D, that neostigmine penetrates the blood-brain barrier, is incorrect as neostigmine, like physostigmine, does not readily cross the blood-brain barrier, limiting its central nervous system effects.
In an educational context, understanding the pharmacological differences between neostigmine and physostigmine is crucial for healthcare professionals managing patients with myasthenia gravis. Neostigmine's additional direct agonistic action on nicotinic receptors makes it a more effective treatment option for this condition, highlighting the importance of selecting the appropriate drug based on its pharmacological properties and mechanism of action.
Option A, that neostigmine is better absorbed orally, is incorrect as both neostigmine and physostigmine are primarily administered parenterally due to poor oral bioavailability.
Option B, stating that neostigmine has a longer duration of action, is also incorrect. Both drugs have a relatively short duration of action, requiring frequent dosing to maintain therapeutic effects.
Option D, that neostigmine penetrates the blood-brain barrier, is incorrect as neostigmine, like physostigmine, does not readily cross the blood-brain barrier, limiting its central nervous system effects.
In an educational context, understanding the pharmacological differences between neostigmine and physostigmine is crucial for healthcare professionals managing patients with myasthenia gravis. Neostigmine's additional direct agonistic action on nicotinic receptors makes it a more effective treatment option for this condition, highlighting the importance of selecting the appropriate drug based on its pharmacological properties and mechanism of action.